Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average - Should You Sell?

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.15 and traded as high as $3.61. Puma Biotechnology shares last traded at $3.55, with a volume of 127,438 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Puma Biotechnology Trading Up 1.4%

The firm has a market cap of $178.17 million, a P/E ratio of 4.66 and a beta of 1.29. The company has a 50 day moving average of $3.35 and a 200 day moving average of $3.17. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53.

Insider Transactions at Puma Biotechnology

In related news, Director Brian M. Stuglik sold 8,100 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.39, for a total value of $27,459.00. Following the completion of the sale, the director directly owned 94,958 shares in the company, valued at approximately $321,907.62. The trade was a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jay M. Moyes sold 22,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $74,800.00. Following the completion of the sale, the director owned 53,322 shares of the company's stock, valued at approximately $181,294.80. This trade represents a 29.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,660 shares of company stock worth $311,563. 23.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its position in shares of Puma Biotechnology by 167.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 6,351 shares during the period. Graham Capital Management L.P. bought a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $33,000. ProShare Advisors LLC bought a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $36,000. C2C Wealth Management LLC bought a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $37,000. Finally, Causeway Capital Management LLC bought a new stake in shares of Puma Biotechnology in the first quarter valued at approximately $42,000. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.